Survey of Non-resuscitation Fluids in Septic Shock
SURF
1 other identifier
observational
200
2 countries
9
Brief Summary
The objective of this study is to survey the type and the amount of non-resuscitation fluids that patients with septic shock receives during their first 5 days of ICU admission.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2018
Shorter than P25 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 9, 2018
CompletedFirst Posted
Study publicly available on registry
February 19, 2018
CompletedStudy Start
First participant enrolled
March 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2018
CompletedAugust 28, 2018
August 1, 2018
5 months
February 9, 2018
August 26, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Type, indication and volume of fluids given to septic shock patients for other reasons than circulatory support.
Type of fluid is defined as either 0.9% normal saline, glucose, Ringers acetate/lactate, enteral nutrition, parenteral nutrition or sterile water. Indication is defined as vehicle, nutrition, maintenance or other. Volume will be reported in ml.
First five days in ICU
Eligibility Criteria
Consecutive patients admitted with septic shock during a 4 month period in ICUs in Sweden and in British Columbia, Canada. A maximum of 30 patients per centre will be recruited.
You may qualify if:
- Septic shock per SEPSIS-3 criteria within 24 hrs of ICU admission
- Informed consent from patient or next of kin if required by local ethical review Board
You may not qualify if:
- Lack of informed consent (see above)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Region Skanelead
Study Sites (9)
St Paul's Hospital
Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
ICU Halmstad Hospital
Halmstad, Sweden
ICU Helsingborg Hospital
Helsingborg, Sweden
ICU Kristianstad Hospital
Kristianstad, Sweden
ICU Skane University Hospital
Lund, Sweden
Department of Infections Diseases
Malmo, Sweden
ICU Skane University Hospital
Malmo, Sweden
ICU Ystad Hospital
Ystad, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Bentzer, MD, PhD
Lund University, Lund, Sweden
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate professor
Study Record Dates
First Submitted
February 9, 2018
First Posted
February 19, 2018
Study Start
March 1, 2018
Primary Completion
July 30, 2018
Study Completion
August 15, 2018
Last Updated
August 28, 2018
Record last verified: 2018-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, CSR
- Time Frame
- Study protocol can be shared from March 1st. Clinical Study Report (CSR) can be shared as data analysis is complete.
- Access Criteria
- On reasonable request
On reasonable request